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n Abstract: Here, we review the prevalence and treatment of anxiety and depression among patients with breast cancer.
Cancer-related symptoms include similarities to responses to traumatic stress. Well-developed screening devices for identi-
fying and tracking psychiatric comorbidity are discussed. Basic principles of psychopharmacology, and individual and group
psychotherapy are presented. Finally, effects of effective treatment of anxiety and depression on quality of life and overall
survival are reviewed. n
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Anxiety and depression are the most commonpsychiatric disorders, and may be induced or
exacerbated by the diagnosis and treatment of breast
cancer. These comorbid illnesses affect quality of life,
adherence to treatment, social support, and survival
time. Effective coping with the disease involves deal-
ing with its direct and indirect effects. Facing breast
cancer and its consequences requires acknowledging
and managing strong but inevitable emotions that can
interfere with medical care (1), family and vocational
engagement, sleep, diet, and exercise (2).
A high prevalence of psychiatric and psychological
problems affect patients and families before, during,
and after cancer care and treatment.
While many would like to maintain a positive view
of the diagnosis and treatment for cancer, for many a
diagnosis of breast cancer constitutes a trauma analo-
gous to experiencing a physical assault, accident, or
natural disaster. Many patients remember the date
and time they received their cancer diagnosis, exactly
where it was discussed, who said it, the specific words
that were used, and how they felt. These life-altering,
life-changing moments are, psychologically riveting. In
the initial period of diagnosis and treatment, the term
acute stress disorder or posttraumatic stress disorder
(PTSD) may best describe the psychological problems
that occur (3). In one study of breast cancer patients
after treatment, 5–10% met diagnostic criteria for
PTSD, (4) and the symptoms changed little over the
ensuing year (5). Such patients experience intrusive
thoughts, disbelief, avoidance, inability to sleep, fears,
and physiological hyperarousal. Their lives change
suddenly from the mundane routine of work or family
activities, to a string of doctors’ appointments, receiv-
ing life-altering news and data in technical language,
making appointments for surgery, blood draws, che-
motherapy, and radiotherapy.
As patients move through the stages of cancer care,
the trauma response may persist from acute stress to a
more chronic PTSD (6–8). Even cessation of acute
treatment can be fraught with anxiety about recur-
rence and withdrawal of active medical support. Yet
many patients and their families also experience what
has been called posttraumatic growth, an altered per-
spective on what matters in life that comes from fac-
ing and dealing with major life stressors (9). This
ability to come to terms with the implications of the
disease and enhance relating to others, appreciation of
life, and spiritual change occurs in a substantial pro-
portion of cancer patients (10,11) and in some cases
predicts better long-term adjustment (12).
SCREENING FOR PSYCHOLOGICAL PROBLEMS
In 1997 the National Comprehensive Cancer Net-
work published the Distress Management Guidelines,
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which is updated regularly as a tool for oncology
clinicians to develop a differential diagnosis of dis-
tress, including common psychiatric disorders and
psychosocial and spiritual problems (nccn.org). More
recently, the NIH has developed a series of brief
reliable and valid measures, the Patient-Reported
Outcomes Measurement System (13,14).
SLEEP
Eighty percent of patients undergoing chemother-
apy and more than two-thirds of women with meta-
static breast cancer experience poor sleep (15,16),
which is associated with numerous negative physical
and mental health outcomes (17,18). Sleep duration
and disruption have been associated with all-cause
mortality (19,20). The precise relationship, however,
is likely complex because some studies have shown
that short sleep duration is implicated in earlier mor-
tality (21), whereas others suggest the relationship is
quadratic, in which both shorter and longer sleep
duration than normal are predictive of shorter survival
(22).
Although precipitating factors for the development
of sleep disruption include stress associated with the
diagnosis of cancer and its treatment (23,24) and cyto-
toxic chemotherapy and its side effects (25), the mech-
anism behind the development of sleep disruption and
how it might affect survival is not well understood
(18). Prior studies found relationships between tumor
characteristics and spread, receptor status, and treat-
ment with survival in metastatic breast cancer (26).
Other studies have shown that circadian dysregulation
measured by flattened cortisol rhythms (27) and
depression (28) are independent prognostic factors for
survival in metastatic breast cancer. We have recently
found that better sleep efficiency and less sleep disrup-
tion as measured by wrist actigraphy are significant
independent prognostic factors of overall survival time
in women with advanced breast cancer (29).
TREATMENT INTERVENTIONS
Psychotropic Medication
Antidepressants It is clear that, as is the case with
major depression in general, depression that arises in
the context of cancer is responsive to antidepressant
treatment (30). Antidepressants decrease depressive
symptoms, improve functional capacity, reduce
cachexia, ameliorate some menopausal symptoms, and
reduce pain (31). Even patients with advanced disease
benefit, despite not having the full range of depressive
symptoms (32). Selective serotonin reuptake inhibitors
may improve depressive symptoms without reducing
fatigue (33).
Antianxiety Agents
Antidepressants have antianxiety properties as well
and can be utilized effectively for the common prob-
lem of mixed anxiety and depression. Benzodiazepines
can provide immediate short-term relief of anxiety
symptoms, but generally are not a good strategy for
long-term treatment, in part because of the likelihood
of habituation and a tendency to produce dependence.
Withdrawal from high doses can be a serious medical
problem, including risk of seizures.
Psychosocial Interventions
The efficacy of psychosocial treatments for depres-
sion and anxiety in medically ill patients, particularly
brief psychodynamic, educational, supportive, and
interpersonal therapies, hypnosis, and behavioral and
cognitive-behavioral methods, has been established in
numerous outcome studies (34–38).
Cognitive-Behavioral Therapy
The cognitive-behavioral approach (39) is built on
the assumption that previous social learning, develop-
mental history, and significant experiences lead peo-
ple to form a dysfunctional set of meanings and
assumptions, or cognitive schemas, about themselves,
the world, and their future. These schemas organize
perception and govern and evaluate behavior (40).
When specific schemas are activated, they directly
influence the content of a person’s perceptions, inter-
pretations, associations, and memories, often in a
way that exacerbates anxiety and depression. The
cognitive behavioral therapy (CBT) therapist seeks to
identify maladaptive cognitions, turn them into test-
able hypotheses, and submit them to open examina-
tion, so the patient can then reject, modify, or retain
these thoughts based on the evidence. More adaptive
cognitions and behaviors are similarly evaluated. In
the early sessions, the goal of CBT is to establish a
therapeutic relationship, identify primary problems,
produce symptom relief, and educate the patient
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about the role of thoughts, images, and beliefs on
emotions and behavior. Together, the therapist and
patient decide on the treatment goal, a plan for sub-
sequent therapy sessions, and homework assignments
intended to consolidate the therapy and direct struc-
tured practice. The initial homework often requires
the patient to identify and record maladaptive cogni-
tions (e.g., automatic thoughts). As therapy contin-
ues, verbal techniques are employed to trigger
automatic thoughts and associated assumptions and
reveal core beliefs or schemas. In an environment of
collaborative empiricism, the patient learns to iden-
tify and evaluate, logically and empirically, the use-
fulness of systematic biases, cognitive distortions and
dysfunctional assumptions, and thoughts, images, and
beliefs that underlie emotional distress. The therapist
helps the patient challenge cognitive distortions such
as overgeneralization, catastrophizing, “should” state-
ments, magnification, minimization, dichotomous
thinking, and the fallacies of excessive control,
worry, fairness, and attachment. Cognitive restructur-
ing techniques and guided discovery help the patient
to choose more adaptive cognitions and behaviors.
Cognitive techniques used in CBT include thought-
stopping, self-instruction, distraction, direct disputa-
tion, labeling distortions, and the development of
replacement imagery. Behavioral techniques including
activity scheduling, relaxation training, social skills
training, mastery and pleasure ratings, assertiveness
training, bibliotherapy, homework, behavioral rehear-
sal, and in vivo exposure are also employed
Group Psychotherapy
Group intervention in a variety of forms has
become an increasingly popular, effective, and efficient
means of providing psychosocial support for breast
cancer patients (41,42). Groups of different types
include psychodynamic, existential, educational, sup-
portive-expressive, and cognitive-behavioral models
(41). Although some cancer patients are initially disin-
clined to join a support group, most are also reluctant
to undertake other aspects of cancer treatment as well.
Many breast cancer patients, especially those with
anxiety and depressive symptoms, need and can bene-
fit from support in dealing with diagnosis and treat-
ment, changes wrought by disease, social isolation,
and existential issues.
Common elements of group psychotherapeutic
intervention include the following (42):
Social Support Psychotherapy, especially in groups,
can provide a new social network cemented by the
common bond of facing similar problems. At a time
when the illness makes a person feel removed from
the flow of life, when many others withdraw out of
awkwardness or fear, group psychotherapeutic sup-
port provides a new and meaningful social connection.
Furthermore, members find that the process of offer-
ing help to others enhances their own sense of mastery
of the role of “patient” and increases their self-esteem.
Emotional Expression The expression of emotion is
important in reducing social isolation and reducing
anxiety and depressive symptoms (43,44). Patients
often have the mistaken belief that they are control-
ling the psychological and even physical impact of the
disease by suppressing their emotional reaction to it.
This attitude is often reinforced by friends and family
who are made anxious by exposure to a patient’s
appropriate fear or sadness. Medical professionals
may perceive a patient’s sadness as an indication of
dissatisfaction with treatment or loss of hope.
Detoxifying Dying Facing rather than avoiding exis-
tential concerns such as dying and death, which could
be considered likely to exacerbate depression, actually
helps to reduce it. This encourages patients to face
what they most fear and find some aspect of it they
can do something about (e.g., control the process of
dying when death is unavoidable). This helps patients
to feel more active and less helpless, even in the face
of dying (42). Death anxiety is intensified by isolation,
in part because patients often conceptualize death in
terms of separation from loved ones. This can be pow-
erfully addressed by directly confronting such con-
cerns in a supportive psychotherapeutic setting (45).
Even the process of grieving for others who have died
of the same condition constitutes a deeply personal
experience of the depth of loss that will be experi-
enced by others after one’s own death.
Reorganizing Life Priorities and Living in the Pres-
ent The acceptance of the possibility of illness short-
ening life carries with it an opportunity for
reevaluating life priorities (46). This can help patients
take control of those aspects of their lives they can
influence, while relinquishing those they cannot (47).
Enhancing Family Support Psychotherapeutic inter-
ventions can also be quite helpful to families in
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improving communication, identifying needs, increas-
ing role flexibility, and adjusting to new medical
social, vocational, and financial realities (48).
Improving Communication with Physicians Support
groups can be quite useful in practicing better commu-
nication with physicians and other health care profes-
sionals (49,50).
SYMPTOM CONTROL
Many group and individual psychotherapy pro-
grams teach specific coping skills designed to help
patients reduce cancer-related symptoms such as anxi-
ety, anticipatory nausea and vomiting, and pain,
which can exacerbate both anxiety and depression.
Techniques used include specific self-regulation skills
such as self-hypnosis, meditation, biofeedback, and
progressive muscle relaxation.
Hypnosis is widely used for pain and anxiety con-
trol in cancer to attenuate the experience of pain and
suffering (51). Instruction in self-hypnosis provides an
effective means of reducing pain and anxiety (52,53).
Hypnosis is an altered state of consciousness, consist-
ing of heightened absorption in focal attention, disso-
ciation of peripheral awareness, and enhanced
responsiveness to social cues (49). It is effective in
controlling somatic symptoms such as pain and anxi-
ety. Patients with the requisite hypnotic capacity can
be taught self-hypnosis exercises to effectively reduce
cancer pain (49,52,53), and to facilitate participation
in medical procedures (54).
Mindfulness Training
Mindfulness-based stress reduction enhances the
ability to live in the moment and to tolerate stresses
as real but transient phenomena, while more comfort-
ably relating to one’s body, often employing gentle
yoga exercises as well (55). Such techniques have been
used effectively with cancer patients. Other studies
have shown that a combination of mindfulness with
more traditional group therapy produces reductions in
intrusive thinking and other posttraumatic stress
symptoms (56), as well as reduced depression, fear of
recurrence, and higher energy (57) among women
with breast cancer. A recent study of mindfulness for
primary breast cancer patients demonstrated greater
reductions in stress symptoms than in an intervention
involving emotional expression or a control group,
and showed that both treatment conditions resulted in
normalization of diurnal cortisol levels.
Electronic Technology-Based Interventions Technol-
ogy-assisted interventions are highly effective and offer
great possibilities for dissemination. A peer-modeling
videotape shown to patients shortly after diagnosis
induced increases in vitality and posttraumatic growth
and decreases in depression and intrusive thoughts
(58). A combination of home visiting and telephone
intervention resulted in reduced pain (59). Computer-
based patient support tools provide information, deci-
sion support, and interaction with other patients and
yield not only increments in knowledge but also better
doctor-patient interactions and enhanced social sup-
port (60). Support groups have been adapted to the
Internet with good effect. For example, online-
mediated social support for cancer-related fatigue have
proven beneficial (61).
OUTCOME
Randomized clinical trials have demonstrated the
benefit of group therapy for breast cancer patients
(45,62–64), with notable reductions in pain (52,53)
and emotional distress (44,65).
IMPLICATIONS FOR OVERALL SURVIVAL
Psychotherapeutic intervention may affect survival
time as well as quality of life (66–70). A year of sup-
portive-expressive group psychotherapy resulted in a
significant 18-month increase in survival time in meta-
static breast cancer patients (66). A randomized repli-
cation trial of supportive-expressive group
psychotherapy among 125 women with metastatic
breast cancer demonstrated positive effects on mood
(44) but no overall survival advantage (71), although
there was a significant interaction with tumor type,
such that those women with estrogen receptor-nega-
tive tumors who had been randomized to the group
condition lived significantly longer than estrogen
receptor-negative controls. A randomized educational
group intervention trial among 227 women with
primary breast cancer demonstrated that group
support resulted in significantly lower rates of relapse
and mortality at 11-year follow-up.
One large multicenter trial that utilized supportive-
expressive group psychotherapy with metastatic breast
cancer patients showed reduced distress and pain but
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no survival advantage (72). However, the treatment
arm in this study was more depressed than the controls
at the beginning of the study, which indicates risk for
shorter survival prior to intervention (28). Taken
together, these studies suggest that psychosocial effects
on survival time are more pronounced when medical
treatments have become less effective (64). No study
has found that psychotherapy shortens survival. The
potential benefit of psychotherapeutic support on can-
cer progression remains an open research question, but
receives further support from recent evidence that
being married is associated with a 12–33% improve-
ment in overall survival in ten kinds of cancer, includ-
ing breast (73). This study involved analysis of SEER
data from 2004 to 2008 involving 734,889 cancer
patients with lung, colorectal, breast, pancreatic, pros-
tate, liver/intrahepatic bile duct, non-Hodgkin lym-
phoma, head/neck, ovarian, or esophageal cancer.
Being married was associated with better outcome
among all ten cancer types, independent of demograph-
ics, stage and treatment. Thus, social support has a tan-
gible effect on disease progression and survival time.
SURVIVORSHIP
Survivorship is an increasingly important aspect of
comprehensive cancer care as cancer survival
improves. Supportive services and surveillance for
anxiety and depression should continue after active
oncologic treatment is completed (74). Domains of
intervention include surveillance for recurrence and
late effects of treatment, genetic issues, overall health
maintenance, attention to psychiatric, social, behav-
ioral, and financial problems, and other factors that
affect mood and other aspects of quality of life. This
includes attention to physical activity, which until
recently has been a neglected area for breast cancer
survivors. There is growing evidence that moderate to
vigorous physical exercise improves health-related
quality of life (75) and reduces depression (76) among
cancer patients. Many survivorship programs are help-
ing patients and their families deal with the aftermath
of treatment through formal survivorship clinics,
classes, group support, nutritional consultation, social
services, and psychiatric support.
CONCLUSION
Anxiety and depression are frequent but treatable
problems that can complicate the lives of breast
cancer patients and their families. Frequent assessment
and early intervention can improve quality of life,
adherence to treatment, and overall outcome.
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